Theme
Interpretable protein design
Est. 2026

Increasing Humanity's Healthspan

Empowering confident lead optimization with explainable in silico designs.

Explore our services Book a meeting

Antibody & protein lead optimization service

Interlit helps reduce costs by designing, screening, and optimizing biologic candidates with our state-of-the-art, independently validated proprietary computational methods.

  • Industry pain point

    Too many candidates

    Generative models now propose thousands of candidates, far more than a lab can afford to test.

    How Interlit can help

    Ranked shortlist before validation

    We design and optimize candidates using state-of-the-art, proprietary computational methods to reduce costs.

  • Industry pain point

    Costly screening assays

    Screening for developability typically relies on resource-intensive, time-consuming lab assays.

    How Interlit can help

    Risk assessment with evidence

    We computationally assess and optimize thermostability, immunogenicity, and developability using explainable, evidence-driven methods to guide confident R&D decisions.

  1. 01

    Binding affinity maturation

    We start from your initial sequences, structures, and assay data to design novel candidates for stronger binding affinity.

  2. 02

    Toxicity and immunogenicity

    Our computational screening platform flags potential toxicity and immunogenicity signals before your team commits to further testing.

  3. 03

    Thermostability optimization

    Residue-level thermostability analysis identifies changes to investigate for greater thermal stability.

  4. 04

    Target engagement

    Molecular dynamics simulations for protein–target interactions help identify contacts and structural hypotheses worth testing.

  5. 05

    Developability

    We assess aggregation, manufacturability, and potential glycosylation and phosphorylation sites to ensure developability.

  6. 06

    Custom solutions

    From split-protein engineering to novel delivery vehicles, we develop new methods for protein engineering specific to your program’s needs.
High binding affinity
Improved thermostability
Low immunogenicity
Low toxicity
High developability
Strong target engagement

About 9 in 10 candidates that enter clinical trials never become medicines.

48% and 55%

of phase II and phase III failures came from a lack of efficacy.

25%

of phase II failures came from safety, the next most common reason.

Our services

We are addressing the pharmaceutical industry's biggest pain points:

Sources: Sun et al., 2022, Acta Pharmaceutica Sinica B 12(7), doi:10.1016/j.apsb.2022.02.002. Harrison, 2016, Nature Reviews Drug Discovery 15, 817 to 818, doi:10.1038/nrd.2016.184. DiMasi et al., 2016, Journal of Health Economics, summarized by the Tufts Center for the Study of Drug Development. Sena et al., 2007, as cited in a 2012 review in European Journal of Nuclear Medicine and Molecular Imaging, PMC3411287.

01

Slow

It takes about 10 years to bring one new medicine to patients (Tufts, 2016).

02

Expensive

Each approved medicine costs about $2.6 billion to develop, counting the candidates that fail (Tufts, 2016).

03

High failure rates

Nine in ten candidates fail somewhere between the first human dose and approval (Sun et al., 2022).

04

Poor early predictions

Of 494 stroke treatments that worked in animals, only 3 showed a convincing effect in patients (Sena et al., 2007).

Candidate screening

We computationally screen biologic candidates.

Binding affinity Thermostability Immunogenicity Toxicity Developability Target engagement Ranked short list, with reasons

A ranking you can interpret

Testing every sequence in the lab is slow and expensive. With a ranking you can interpret, you test only the designs that rank highest, cutting lab expenditure, accelerating your research cycle, and reaching patent priority before your competitors.

Book a meeting

Candidate B-07 Ranked 1 of 10,000

Example reportNot a real candidate

Binding affinity
0.8 nM
Developability
90/100
Immunogenicity
0 epitopes
Toxicity
0 of 24 off-targets
Thermostability
ΔΔG=−1.2 kcal/mol
Target engagement
96 % occupancy

Hypothetical example for illustration only: invented data, not a real candidate. Folding ΔΔG is the variant’s folding free energy minus that of the starting antibody; negative values indicate stabilization.

Track record

Our technologies surpassed several world records, validated by an independent lab.

In the 2026 EGFR/cetuximab binder optimization competition, three of our ten designs surpassed the previous world best, and the candidate we ranked first proved to be the tightest binder measured, at 43.9 times tighter than the cetuximab starting antibody and 1.6 times tighter than the best prior design, all done in under one day.

Affinity against the 9.94 nM cetuximab parent, as fold improvement (wet-lab Kd, measured independently by Adaptyv with SPR, two replicates per design). Three of our ten designs beat the previous best public design, 0.37 nM. The Interlit bars show our ranking (#1, #6, #9), and our #1 was the tightest binder measured. Read the full results.

The people

Meet the team

Supported byETH ZürichETH Zürich Student Project House

From the blog

Our latest research notes.

  1. 30 September 2026Dissociation rate drives binding affinity differences among optimized cetuximab-derived EGFR binders
  2. 30 July 2026Two Scientific Innovators, One Shared Mission
  3. 18 July 2026The Score Most People Use to Rank Protein Binders Doesn’t Predict Binding
  4. 14 July 2026In Under a Day, We Set Three World Records in Protein Design
 All articles

Questions

Frequently asked questions

Interlit is a Zürich company that develops novel methods, user-friendly software, and interpretable AI models to design biologic medicines.

We start from your target and your binding or screening data, then optimize and rank designs from there.

Each candidate comes with the assessments behind its rank: binding affinity, thermostability, immunogenicity, toxicity, developability, and target engagement. You can see why one design ranks above another.

We are taking early requests. Join the waiting list or ask about a screening project through the contact form.

Contact

Contact us or join our waiting list.

The values below guide our work and every product decision.

  1. Staying trueWe stay true to ourselves, to you and to our mission.
  2. CuriosityWe keep learning, exploring, and inventing new things, and we challenge assumptions.
  3. Thinking differentlyWe question established dogmas and the status quo.
  4. Quality and aestheticsWe believe great science deserves exceptional design, precision, and craftsmanship.

We are happy to hear from you. Fill out this short form to join the waiting list or send us a question.

Get started

Takes about 3 minutes

Increasing Humanity's Healthspan

Every test consumes time, material, and budget. Interlit improves your starting antibodies by designing, screening, and optimizing them with state-of-the-art proprietary computational methods, helping you enter preclinical development with greater confidence.

Book a meeting